Month: December 2022

Agora, Inc. Announces Changes to Board of Directors

Agora, Inc. Announces Changes to Board of Directors

SANTA CLARA, Calif., Dec. 30, 2022 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API) (“Agora”), a pioneer and leading platform for real-time engagement APIs, today announced a change in its board of directors. Ms. Jenny Hong Wei Lee has tendered her voluntary resignation from Agora’s board of directors due to personal reasons, effective as of today. Mr. Steve Zhang has been appointed as a director on Agora’s board of directors and will serve as a member of the audit committee and compensation committee, effective as of today. Mr. Steve Zhang has over 30 years of experience in the global information technology industry and had served in senior executive roles at leading information technology firms in Asia and the United States. “On behalf of the board, we sincerely thank Jenny for her dedicated service and invaluable advice to our board...

Continue reading

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

SPU-21 effective in controlling arthritis progression.  SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide  ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. Silo Pharma is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).  In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis...

Continue reading

Sparton Resources Inc. Announces First Tranche of Private Placement Financing Closed

Sparton Resources Inc. Announces First Tranche of Private Placement Financing Closed

TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV.SRI) (“Sparton” or the “Company“) announced today that it has closed, effective December 30, 2022, the first tranche of a $500,000 private placement financing through the sale of 1,100,000 Flow Through Share Units (“the Units”) to a number of individual accredited investors (the “Investors”) for total proceeds of $88,000. Please see Sparton news release dated December 1, 2022. Each Unit consists of one common share of the Company priced at $0.08 and a one-half Share Purchase Warrant (“SPW”). Two SPWs will entitle the warrant holder to purchase one additional Sparton common share at a price of $0.12 until December 30, 2024. The placement was non-brokered and commissions and finder’s fees of 7% cash and 7% in SPWs may be payable on a portion...

Continue reading

Revival Gold 2022 Year in Review

Revival Gold 2022 Year in Review

TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide a summary of the Company’s key accomplishments in 2022 to advance the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. Highlights Beartrack-Arnett Indicated Mineral Resources increased to 65.0 million tonnes at 1.01 g/t gold containing 2.11 million ounces of gold1, up 56% over the 2020 Indicated Mineral Resource2, and Inferred Mineral Resources increased to 46.2 million tonnes at 1.31 g/t gold containing 1.94 million ounces of gold1, up 19% over the 2020 Inferred Mineral Resource2 On the main Beartrack-Arnett trend of mineralization, four core drill holes were completed for 2,600 meters of drilling. Follow-up drilling at Joss continued to demonstrate the high-grade...

Continue reading

Connect Biopharma Provides Business and Clinical Development Program Update

Connect Biopharma Provides Business and Clinical Development Program Update

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of China pivotal AD trial remains on track with completion of 36-week Stage 2 expected in H2 2023 SAN DIEGO and TAICANG, SUZHOU, China, Dec. 30, 2022 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today provided a business update for its operations and clinical trial development programs. “We continue to have great confidence in our global development strategy, and particularly...

Continue reading

BiondVax CEO Issues Letter to Shareholders

BiondVax CEO Issues Letter to Shareholders

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, successful preclinical trial results of the inhaled COVID-19 NanoAb therapy as well as recent financing activities to support 2023 objectives. The letter reads as follows:  Dear BiondVax Shareholders,  BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.  My optimism is based on our people, our partnerships and BiondVax’s remarkable turnaround. When I became CEO in 2021, I...

Continue reading

Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, announces an organizational change in Avicanna LATAM S.A.S. with Lucas Nosiglia stepping down as President of Avicanna LATAM S.A.S. effective January 31, 2023 and transitioning to another role within the Company. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization...

Continue reading

Futu Provides Regulatory Update in China

Futu Provides Regulatory Update in China

HONG KONG, Dec. 30, 2022 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today makes the following announcement: Futu noted that the China Securities Regulatory Commission (the “CSRC”) posted an announcement on December 30, 2022 relating to the Company’s cross-border operations in mainland China. Futu will fully cooperate with the CSRC and take all necessary measures to review its cross-border operations in mainland China and to comply with all applicable rules and regulations. The Company will proactively seek guidance from and cooperate with the CSRC in connection with its efforts to ensure legal compliance of its business activities in mainland China. In the meantime, the Company will continue to provide high-quality services...

Continue reading

AVENIR LNG LIMITED REPORTS UNAUDITED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2022

AVENIR LNG LIMITED REPORTS UNAUDITED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2022

December 30th, 2022, – Avenir LNG Limited and its subsidiaries (NOTC: AVENIR) (“Avenir” or the “Company or Group”), supplies small-scale LNG to off-grid industry, power generation and transport fuel sectors as well as providing infrastructure to support the development of LNG as a marine fuel, today announced its unaudited financial and operating results for the third quarter ended September 30, 2022. Peter Mackey, Chief Executive Officer of Avenir commented: “Avenir is pleased to report operating revenues of $20.9 million and EBITDA of $5.1 million for Q3 2022. This marks the 1st full quarter in our history with all of our assets in service, a significant milestone for the company. Global gas and LNG markets remained highly volatile throughout Q3 with the European gas benchmarking once again reaching extraordinarily high price levels....

Continue reading

CTO Realty Growth Announces Acquisition of The Collection At Forsyth in Atlanta, Georgia for $96.0 Million

CTO Realty Growth Announces Acquisition of The Collection At Forsyth in Atlanta, Georgia for $96.0 Million

WINTER PARK, Fla., Dec. 30, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced it has acquired The Collection at Forsyth, a 560,000 square foot lifestyle, mixed-use property in the Forsyth County submarket of Atlanta, Georgia (the “Property”) for a purchase price of $96.0 million. The purchase price represents a going-in cap rate above the range of the Company’s current guidance for initial cash yields. “Our acquisition of The Collection at Forsyth is an exciting opportunity to invest in a high-quality asset meaningfully below replacement cost where we believe there is future upside by repositioning the property through targeted capital investment, improving the overall tenant mix, and leasing the existing vacancy,” said John P. Albright, President and Chief Executive Officer of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.